fulvestrant has been researched along with vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-o-methyl-tyr(2)-thr(4)-orn(8)-tyr(9)-nh2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danalache, B; Gangal, M; Gutkowska, J; Jankowski, M; Wang, D | 1 |
1 other study(ies) available for fulvestrant and vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-o-methyl-tyr(2)-thr(4)-orn(8)-tyr(9)-nh2
| Article | Year |
|---|---|
Cardiac oxytocin receptor blockade stimulates adverse cardiac remodeling in ovariectomized spontaneously hypertensive rats.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fibrosis; Fulvestrant; Genistein; Hypertension; Myocardial Contraction; Myocardium; Natriuretic Peptide, Brain; Ovariectomy; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Oxytocin; RNA, Messenger; Vasotocin; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2010 |